The role of atypical antipsychotics in glucose/insulin dysregulation and the evolving role of the psychiatrist in a new era of drug treatment options

CNS Spectrums

Volumn 9, Issue 11, 2004, Pages 849-861

  Ferraioli, Anthony ^a,b,c   Shirley, Kara Lee ^d,e,f   David, Panakkal ^g  

^a Albany Co Dept of Mental Health   (United States)

^b Shaker Park Medical ^*  (United States)

^c St Peter's Hospital Albany   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e Capital District Psychiatric Center   (United States)

^f SAGE Graduate School of Nursing   (United States)

^g ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; LEPTIN; NEUROLEPTIC AGENT; SEROTONIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

AGING; DRUG CHOICE; DRUG MONITORING; ETHNOLOGY; FAMILY HISTORY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL CARE; MENTAL PATIENT; METABOLIC SYNDROME X; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 10044249035     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900002261     Document Type: Review

References (61)

1. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2):S135-S148.
2. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry. 2001;62(suppl 27):5-9.
3. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45:21-28.
4. Melkersson KI, Hulting A, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
5. Semyak MJ, Gulanski B, Leslie D, Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry. 2003;64:605-608.
6. Semyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
7. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-912.
8. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1999;60:217-234.
9. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172-1176.
10. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299.
11. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
12. Melkersson KI, Hulting A, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;60:783-791.
13. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
14. American Diabetes Association. Clinical Practice Recommendations 2003. Journal of Clinical and Applied Research and Education. 2003;26(suppl 1):S1-S156.
15. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111:716-723.
16. Koller E, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
17. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.
18. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92-100.
19. Olefsky JM. Insulin resistance. In: Diabetes Mellitus. 5th ed. Stamford, Conn: Appleton and Lange; 1997:513-552.
20. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care. 1996;19:387-389.
21. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-296.
22. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective databse analysis. J Clin Psychiatry. 2002;63:1135-1139.
23. Kenny SJ, Aubert RE, Geiss LS. Prevlance and incidence of non-insulin-dependent diabetes. In: Harris M, Cowie C, Stern M, Boyko E, Reiber G, Bennett P, eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes Health; 1995:47-67. Publication No. 95-1468.
24. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
25. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci Lett. 1999;274:151-154.
26. Brismar K, Grill V, Efendic S, Hall K. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism. 1991;40:728-732.
27. Hilding A, Brismar K, Degerblad M, Thoren M, Hall K. Altered relation between circulating levels of insulin-like growth factor binding protein-1 and insulin in growth hormone deficient patients and insulin dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab. 1995;80:2646-2652.
28. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology. 1996;63:269-274.
29. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci. 1991;49:101-109.
30. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374:542-546.
31. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes. 1996;45:699-701.
32. Tanizawa Y, Okuya S, Ishihara H, Asano T, Yada T, Oka Y. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells. Endocrinology. 1997;138:4513-4516.
33. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab. 1999;84:670-676.
34. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuro-Psychopharmacol Biol Psychiatry. 1999;23:69-80.
35. Gould RJ, Murphy KM, Reynolds IJ, Snyder SH. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A. 1983;80:5122-5125.
36. Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M. Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc Natl Acad Sci U S A. 1986;83:7513-7517.
37. Newcomer JW. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. 2001;62(suppl 27):3-4; discussion 40-41.
38. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl27):35-39; discussion 40-41.
39. Zoler M. Antipsychotics linked to weight gain, diabetes. Clinical Psychiatry News. 1999;27:20.
40. American Diabetes Association. Screening for Type 2 Diabetes. Diabetes Care. 2003;26(suppl 1):S21-S24.
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
42. Werneke U, Taylor D, Sanders TA. Options for the pharmacological management of obesity in patients treated with atypical antipsychotics. Curr Psychiatry. 2002;8:145-160.
43. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2002.
44. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
45. Actos [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc. and Indianapolis, Ind: Eli Lilly and Co.; July 2002.
46. Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med. 2001;111:584-585.
47. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-121.
48. Vieweg W, Adler R, Fernandez A. Weight control and antipsychotics: how to tip the scales away from diabetes and heart disease. Curr Psychiatry. 2002;1:10-19.
49. Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep. 2002;4:279-283.
50. Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord. 1999;2:123-124.
51. Frankenburg FR, Zanarini MC. Uses of clozapine in nonschizophrenic patients. Harv Rev Psychiatry. 1994;2:142-150.
52. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103-107.
53. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry. 2000;61:329-334.
54. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-288.
55. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry. 2001;62(suppl 23):45-64.
56. Rusnak JM, Kisabeth RM, Herbert DP, McNeil DM. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. Mayo Clin Proc. 2001;76:299-309.
57. Basile VS, Masellis M, Ozdemir V, et al. Application of pharmacogenetics to schizophrenia: emerging insights from studies of clozapine and tardive dyskinesia. In: Breier A, Brier A, Bymaster F, Tran P, Lewis M, eds. Current Issues in the Psychophamacology of Schizophrenia. New York, NY: Lippincott Williams & Wilkens; 2001:85-110.
58. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry. 2000;47:252-266.
59. Arranz MJ, Munro J, Osborne S, Collier D, Kenvin RW. Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin Pharmacother. 2001;2:537-542.
60. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C-receptor gene polymorphism. Lancet. 2002;359:2086-2087.
61. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia. 2000;43:373-376.